<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="sps-1.9" dtd-version="1.1" xml:lang="pt" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
        <publisher-loc>S&#227;o Paulo, SP, Brazil</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">yvcZSmWPzQgZDV4f5XD7rNt</article-id>
      <article-id pub-id-type="other">00006</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2011000100006</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v1">S0066-782X(11)09600106</article-id>
      <article-id pub-id-type="doi">10.1590/S0066-782X2010005000160</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Artigos Originais</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Doen&#231;a coron&#225;ria obstrutiva em hepatopatas cr&#244;nicos que aguardam transplante hep&#225;tico</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Godoy</surname>
            <given-names>Moacir Fernandes de</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
          <xref ref-type="aff" rid="aff02"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Roveri</surname>
            <given-names>Patricia de Oliveira</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Santos</surname>
            <given-names>Marcio Antonio dos</given-names>
          </name>
          <xref ref-type="aff" rid="aff02"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pivatelli</surname>
            <given-names>Flavio Correa</given-names>
          </name>
          <xref ref-type="aff" rid="aff02"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Silva</surname>
            <given-names>Rita de C&#225;ssia Martins Alves da</given-names>
          </name>
          <xref ref-type="aff" rid="aff02"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Silva</surname>
            <given-names>Renato Ferreira da</given-names>
          </name>
          <xref ref-type="aff" rid="aff02"/>
        </contrib>
      </contrib-group>
      <aff id="aff01">
        <addr-line>
          <named-content content-type="state">S&#227;o Paulo</named-content>
        </addr-line>
        <institution content-type="orgname">Faculdade de Medicina de S&#227;o Jos&#233; do Rio Preto</institution>
        <country country="BR">Brazil</country>
      </aff>
      <aff id="aff02">
        <addr-line>
          <named-content content-type="city">S&#227;o Jos&#233; do Rio Preto</named-content>
          <named-content content-type="state">S&#227;o Paulo</named-content>
        </addr-line>
        <institution content-type="orgname">Faculdade de Medicina de S&#227;o Jos&#233; do Rio Preto</institution>
        <country country="BR">Brazil</country>
      </aff>
      <pub-date date-type="collection" publication-format="electronic">
        <month>01</month>
        <year>2011</year>
      </pub-date>
      <volume>96</volume>
      <issue>1</issue>
      <fpage>26</fpage>
      <lpage>30</lpage>
      <history>
        <date date-type="received">
          <day>11</day>
          <month>07</month>
          <year>2009</year>
        </date>
        <date date-type="accepted">
          <day>17</day>
          <month>06</month>
          <year>2010</year>
        </date>
        <date date-type="rev-recd">
          <day>16</day>
          <month>06</month>
          <year>2010</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" xml:lang="en">
          <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>FUNDAMENTO: A insufici&#234;ncia hep&#225;tica avan&#231;ada (IHA) geralmente cursa com hipocolesterolemia. Apesar disso, uma parcela dos pacientes com IHA desenvolve coronariopatia obstrutiva de grau importante com consequente aumento de risco ou at&#233; contraindica&#231;&#227;o para transplante hep&#225;tico. OBJETIVO: Analisar a contribui&#231;&#227;o dos fatores de risco cl&#225;ssicos para doen&#231;a arterial coronariana (DAC) em pacientes portadores de IHA com e sem coronariopatia obstrutiva. M&#201;TODOS: Avalia&#231;&#227;o dos fatores de risco para DAC em 119 pacientes, em um servi&#231;o de refer&#234;ncia para transplante hep&#225;tico, com as seguintes caracter&#237;sticas: mais de 40 anos de idade, portadores de IHA e submetidos a cinecoronariografia. RESULTADOS: Coronariopatia obstrutiva foi detectada em 21 (17,6%) dos casos. Esses pacientes apresentavam realmente n&#237;veis baixos de colesterol, sendo de 129,0 &#177; 53,5 mg/dl com mediana de 117,0 mg/dl nos hepatopatas com coron&#225;rias normais e 135,4 &#177; 51,7 mg/dl com mediana de 122,0 mg/dl nos hepatopatas com coronariopatia obstrutiva (P=0,8215). Na regress&#227;o log&#237;stica multivariada, a idade, o sexo, o &#237;ndice de massa corporal, bem como as presen&#231;as de diabete, de tabagismo e de etilismo n&#227;o tiveram signific&#226;ncia estat&#237;stica isolada na diferencia&#231;&#227;o entre os grupos. Tamb&#233;m n&#227;o houve associa&#231;&#227;o com a etiologia da IHA. Por sua vez, a hipertens&#227;o arterial mostrou-se relevante na associa&#231;&#227;o com DAC (P=0,0474). CONCLUS&#195;O: Apenas a hipertens&#227;o arterial foi fator de risco com signific&#226;ncia estat&#237;stica para o desenvolvimento de DAC em pacientes com IHA aguardando transplante hep&#225;tico. Por ser um fator de risco modific&#225;vel, esse achado orienta a pr&#225;tica de atitudes terap&#234;uticas na tentativa de evitar ou retardar o desenvolvimento da DAC nesses pacientes.</p>
      </abstract>
      <kwd-group xml:lang="pt" kwd-group-type="author-generated">
        <kwd>Doen&#231;a da art&#233;ria coronariana</kwd>
        <kwd>hepatopatias</kwd>
        <kwd>transplante de f&#237;gado</kwd>
        <kwd>fatores de risco</kwd>
      </kwd-group>
      <pub-date publication-format="electronic" date-type="pub">
        <day>10</day>
        <month>12</month>
        <year>2010</year>
      </pub-date>
    </article-meta>
  </front>
  <body>
    <p>Doen&#231;a coron&#225;ria obstrutiva em hepatopatas cr&#244;nicos que aguardam transplante hep&#225;tico</p>
    <p>
      <bold>Moacir Fernandes de Godoy<sup>I,II</sup>; Patricia de Oliveira Roveri<sup>I</sup>; Marcio Antonio dos Santos<sup>II</sup>; Flavio Correa Pivatelli<sup>II</sup>; Rita de C&#225;ssia Martins Alves da Silva<sup>II</sup>; Renato Ferreira da Silva<sup>II</sup></bold>
    </p>
    <p><sup>I</sup>Faculdade de Medicina de S&#227;o Jos&#233; do Rio Preto (FAMERP) </p>
    <p><sup>II</sup>Funda&#231;&#227;o Faculdade Regional de Medicina (FUNFARME), S&#227;o Jos&#233; do Rio Preto, SP - Brasil</p>
    <p>
      <xref ref-type="corresp" rid="nt">Correspond&#234;ncia</xref>
    </p>
    <p>
      <bold>RESUMO</bold>
    </p>
    <p><bold>FUNDAMENTO:</bold> A insufici&#234;ncia hep&#225;tica avan&#231;ada (IHA) geralmente cursa com hipocolesterolemia. Apesar disso, uma parcela dos pacientes com IHA desenvolve coronariopatia obstrutiva de grau importante com consequente aumento de risco ou at&#233; contraindica&#231;&#227;o para transplante hep&#225;tico. </p>
    <p><bold>OBJETIVO:</bold> Analisar a contribui&#231;&#227;o dos fatores de risco cl&#225;ssicos para doen&#231;a arterial coronariana (DAC) em pacientes portadores de IHA com e sem coronariopatia obstrutiva. </p>
    <p><bold>M&#201;TODOS: </bold>Avalia&#231;&#227;o dos fatores de risco para DAC em 119 pacientes, em um servi&#231;o de refer&#234;ncia para transplante hep&#225;tico, com as seguintes caracter&#237;sticas: mais de 40 anos de idade, portadores de IHA e submetidos a cinecoronariografia. </p>
    <p><bold>RESULTADOS:</bold> Coronariopatia obstrutiva foi detectada em 21 (17,6%) dos casos. Esses pacientes apresentavam realmente n&#237;veis baixos de colesterol, sendo de 129,0 &#177; 53,5 mg/dl com mediana de 117,0 mg/dl nos hepatopatas com coron&#225;rias normais e 135,4 &#177; 51,7 mg/dl com mediana de 122,0 mg/dl nos hepatopatas com coronariopatia obstrutiva (P=0,8215). Na regress&#227;o log&#237;stica multivariada, a idade, o sexo, o &#237;ndice de massa corporal, bem como as presen&#231;as de diabete, de tabagismo e de etilismo n&#227;o tiveram signific&#226;ncia estat&#237;stica isolada na diferencia&#231;&#227;o entre os grupos. Tamb&#233;m n&#227;o houve associa&#231;&#227;o com a etiologia da IHA. Por sua vez, a hipertens&#227;o arterial mostrou-se relevante na associa&#231;&#227;o com DAC (P=0,0474). </p>
    <p><bold>CONCLUS&#195;O:</bold> Apenas a hipertens&#227;o arterial foi fator de risco com signific&#226;ncia estat&#237;stica para o desenvolvimento de DAC em pacientes com IHA aguardando transplante hep&#225;tico. Por ser um fator de risco modific&#225;vel, esse achado orienta a pr&#225;tica de atitudes terap&#234;uticas na tentativa de evitar ou retardar o desenvolvimento da DAC nesses pacientes.</p>
    <p><bold>Palavras-chave:</bold> Doen&#231;a da art&#233;ria coronariana; hepatopatias, transplante de f&#237;gado, fatores de risco.</p>
    <p>
      <bold>Introdu&#231;&#227;o</bold>
    </p>
    <p>A doen&#231;a arterial coronariana (DAC) &#233; a causa mais comum de isquemia do mioc&#225;rdio, podendo culminar em infarto do mioc&#225;rdio, al&#233;m de ser a principal causa de morte na civiliza&#231;&#227;o ocidental. A DAC &#233; caracterizada pela forma&#231;&#227;o de dep&#243;sitos de gordura (ateromas) na parede das art&#233;rias, obstruindo gradativamente a sua luz, principalmente nas de m&#233;dio calibre, entre as quais est&#227;o as coron&#225;rias<sup>1</sup>.</p>
    <p>Os fatores de risco para DAC incluem hipercolesterolemia, com aumento dos n&#237;veis da lipoprote&#237;na de baixa densidade (LDL) plasm&#225;tica, tabagismo, hipertens&#227;o arterial, diabete, obesidade, sedentarismo, n&#237;veis s&#233;ricos de triglicer&#237;deos aumentados, predisposi&#231;&#227;o gen&#233;tica, idade e sexo masculino, entre os quais se destaca a hipercolesterolemia<sup>1</sup>.</p>
    <p>Os altos n&#237;veis s&#233;ricos de LDL tamb&#233;m s&#227;o capazes de aumentar a capacidade de ades&#227;o dos mon&#243;citos circulantes, que se aderem &#224;s c&#233;lulas endoteliais lesadas, s&#227;o atra&#237;dos por quimiotaxia para a regi&#227;o subendotelial, se acumulam e se tornam macr&#243;fagos, que fagocitam LDL at&#233; se tornarem "c&#233;lulas espumosas" ou <italic>foam cells</italic>. Esses macr&#243;fagos s&#227;o, ainda, respons&#225;veis pela libera&#231;&#227;o de diversos fatores de crescimento, que atuam nas c&#233;lulas musculares lisas e fibroblastos, formando mais tecido conectivo e originando placas fibrosas<sup>1</sup>.</p>
    <p>Uma terceira a&#231;&#227;o dos elevados n&#237;veis de LDL ocorre sobre as plaquetas. Ap&#243;s a les&#227;o endotelial, em decorr&#234;ncia da retra&#231;&#227;o das c&#233;lulas endoteliais, as plaquetas podem entrar em contato com as c&#233;lulas espumosas, o que culmina com a ades&#227;o, a agrega&#231;&#227;o e, finalmente, a forma&#231;&#227;o de um trombo mural, que oclui a luz da art&#233;ria. Esse ciclo todo que leva &#224; forma&#231;&#227;o das placas ateromatosas pode se repetir continuamente, propiciando oclus&#227;o progressiva do vaso<sup>1</sup>.</p>
    <p>A insufici&#234;ncia hep&#225;tica, em contrapartida, &#233; uma doen&#231;a que se caracteriza por uma grave perda da fun&#231;&#227;o do f&#237;gado, devido a algum tipo de dist&#250;rbio como hepatites virais, cirrose e hepatopatia medicamentosa ou alco&#243;lica<sup>2</sup>.</p>
    <p>O f&#237;gado &#233; o local mais ativo de metabolismo do colesterol e, em casos de insufici&#234;ncia hep&#225;tica avan&#231;ada, a perda de fun&#231;&#227;o desse &#243;rg&#227;o leva &#224; redu&#231;&#227;o dos n&#237;veis plasm&#225;ticos de colesterol.</p>
    <p>A mortalidade da insufici&#234;ncia hep&#225;tica varia entre 40 e 80%, e o transplante de f&#237;gado consiste na &#250;nica alternativa terap&#234;utica capaz de proporcionar ao paciente portador dessa doen&#231;a uma melhora significativa da sobrevida<sup>3</sup>. O transplante &#233; o tratamento estabelecido para doen&#231;as avan&#231;adas do f&#237;gado e insufici&#234;ncia hep&#225;tica, de modo que, nos Estados Unidos, s&#227;o realizados 4.000 transplantes de f&#237;gado anualmente<sup>4</sup>. </p>
    <p>A cirrose hep&#225;tica pode ser de origem alco&#243;lica. Sabe-se que a ingest&#227;o moderada de &#225;lcool tem efeito ben&#233;fico sobre a aterosclerose, por elevar os n&#237;veis de lipoprote&#237;na de alta densidade (HDL) plasm&#225;tica, o que seria mais uma contradi&#231;&#227;o para a ocorr&#234;ncia de doen&#231;a arterial coronariana em pacientes com insufici&#234;ncia hep&#225;tica. A fun&#231;&#227;o do HDL consiste em fazer o transporte reverso do colesterol, levando-o dos tecidos para o f&#237;gado, onde &#233; metabolizado e excretado<sup>1</sup>. Isso explica porque os n&#237;veis adequados de HDL reduzem os riscos para aterosclerose.</p>
    <p>Com base nestes dados, n&#227;o seria esperado encontrar aterosclerose em pacientes com insufici&#234;ncia hep&#225;tica &#224; espera de transplante de f&#237;gado. Entretanto, foi encontrada uma preval&#234;ncia geral de 16,2% de doen&#231;a arterial coronariana grave (obstru&#231;&#227;o maior que 70% das coron&#225;rias) em pacientes acima de 50 anos em avalia&#231;&#227;o pr&#233;-operat&#243;ria para transplante de f&#237;gado, diagnosticada por cateterismo<sup>5</sup>. Plotkin e cols<sup>6</sup>. encontraram, com base em cateterismo card&#237;aco e em ecocardiograma de estresse com dobutamina, 5% de doen&#231;a arterial coronariana significativa (com obstru&#231;&#227;o de 70% ou mais das coron&#225;rias) em pacientes acima de 40 anos<sup>6</sup>.</p>
    <p>Sabe-se que a mortalidade cir&#250;rgica de hepatopatas cr&#244;nicos submetidos a transplante hep&#225;tico &#233; maior na presen&#231;a de coronariopatia obstrutiva, e essa mortalidade por doen&#231;a cardiovascular continua a se expressar no p&#243;s-operat&#243;rio tardio dos transplantados<sup>7</sup>.</p>
    <p>A doen&#231;a arterial coronariana diagnosticada em pacientes em avalia&#231;&#227;o pr&#233;-operat&#243;ria para transplante de f&#237;gado, apesar de ser muitas vezes considerada uma contraindica&#231;&#227;o absoluta, n&#227;o precisa necessariamente ser encarada como tal, mas se sabe que os riscos de morbidade e mortalidade em transplantes de f&#237;gado em pacientes com doen&#231;a arterial coronariana s&#227;o aumentados significativamente, sendo igualmente elevados nos casos em que o transplante &#233; realizado ap&#243;s tratamento medicamentoso ou cir&#250;rgico da doen&#231;a arterial coronariana<sup>8</sup>. Entretanto, ainda n&#227;o h&#225; defini&#231;&#227;o a respeito de qual fator de risco mais bem prediz a presen&#231;a de coronariopatia obstrutiva em pacientes com insufici&#234;ncia hep&#225;tica avan&#231;ada<sup>9</sup>.</p>
    <p>Assim, o objetivo do presente estudo foi analisar pacientes com insufici&#234;ncia hep&#225;tica avan&#231;ada com e sem diagn&#243;stico de doen&#231;a arterial coronariana associada, em busca dos fatores de risco que poderiam justificar o desenvolvimento das obstru&#231;&#245;es.</p>
    <p>
      <bold>Materiais e m&#233;todos</bold>
    </p>
    <p>Foram revisados 119 prontu&#225;rios de pacientes com mais de 40 anos, portadores de insufici&#234;ncia hep&#225;tica avan&#231;ada (IHA), que aguardavam em fila para transplante de f&#237;gado e que tinham sido submetidos a cateterismo card&#237;aco como parte dos procedimentos de avalia&#231;&#227;o cl&#237;nica pr&#233;-operat&#243;ria. O protocolo de avalia&#231;&#227;o cl&#237;nica pr&#233;-transplante hep&#225;tico em nosso servi&#231;o inclu&#237;a a realiza&#231;&#227;o de cateterismo card&#237;aco em todos os pacientes acima de 40 anos, uma vez que o teste de esfor&#231;o muitas vezes &#233; invi&#225;vel nesse grupo, al&#233;m disso, muito frequentemente est&#227;o em uso de vasodilatadores e betabloqueadores. </p>
    <p>Essa revis&#227;o de prontu&#225;rios foi realizada em busca da presen&#231;a ou aus&#234;ncia de fatores de risco para doen&#231;a arterial coronariana. Os fatores considerados foram: idade, sexo, hipertens&#227;o arterial, diabete, &#237;ndice de massa corp&#243;rea (IMC), tabagismo, etilismo, n&#237;veis s&#233;ricos de colesterol total, HDL, LDL e triglic&#233;rides, bem como a causa da insufici&#234;ncia hep&#225;tica.</p>
    <p>Para calcular a frequ&#234;ncia com que a coronariopatia pode ocorrer, foram considerados apenas os pacientes com obstru&#231;&#227;o coronariana com 50% ou mais da luz de, pelo menos, um ramo principal comprometidos.</p>
    <p>Na an&#225;lise estat&#237;stica, as vari&#225;veis quantitativas cont&#237;nuas com distribui&#231;&#227;o gaussiana foram estudadas com aux&#237;lio do teste <italic>t</italic> de <italic>Student</italic>, enquanto as qualitativas nominais (ou ordinais) ou as quantitativas sem distribui&#231;&#227;o gaussiana foram estudadas com aux&#237;lio do teste exato de <italic>Fisher</italic> ou teste de <italic>Mann-Whitney</italic>. A avalia&#231;&#227;o foi complementada com um teste de regress&#227;o log&#237;stica m&#250;ltipla.</p>
    <p>Os n&#237;veis de coorte utilizados foram: colesterol total acima de 200 mg/dl, HDL abaixo de 40 mg/dl, LDL acima de 130 mg/dl e triglic&#233;rides acima de 150 mg/dl. Foram considerados hipertensos os pacientes com press&#227;o arterial sist&#243;lica de 140 mmHg ou maior; ou com press&#227;o arterial diast&#243;lica de 90 mmHg ou maior; ou, ent&#227;o, em uso de medica&#231;&#227;o hipotensora. Foram definidos como diab&#233;ticos os pacientes com n&#237;veis de glicemia acima de 126 mg/dl ou em uso de hipoglicemiantes orais ou insulina. Foram considerados fumantes os pacientes que fumavam qualquer quantidade de cigarros ou que tinham abandonado at&#233; menos de um ano antes da cinecoronariografia. Foram considerados etilistas os que consumiam mais que duas doses de &#225;lcool ao dia. Para utiliza&#231;&#227;o na regress&#227;o log&#237;stica, a idade foi considerada at&#233; 55 anos (0) e mais que 55 anos (1); o IMC foi considerado at&#233; 29,9 kg/m<sup>2</sup> (0) e 30 ou mais kg/m<sup>2</sup> (1). Os valores de lip&#237;deos n&#227;o foram inclu&#237;dos na regress&#227;o log&#237;stica, pois como regra geral estavam frequentemente bem abaixo dos limites m&#225;ximos da normalidade.</p>
    <p>Para analisar as causas de insufici&#234;ncia hep&#225;tica avan&#231;ada, os pacientes foram divididos em quatro grupos: portadores de v&#237;rus (incluindo v&#237;rus B, v&#237;rus C ou ambos), etilistas, pacientes com associa&#231;&#227;o de v&#237;rus e &#225;lcool e pacientes com insufici&#234;ncia hep&#225;tica idiop&#225;tica ou criptog&#234;nica. Admitiu-se erro alfa de 5%, sendo considerados significantes valores de P <underline>&lt;</underline> 0,05. A pesquisa foi aprovada pelo Comit&#234; de &#201;tica da Institui&#231;&#227;o.</p>
    <p>
      <bold>Resultados</bold>
    </p>
    <p>A ocorr&#234;ncia de coronariopatia nos 119 pacientes com idade superior a 40 anos e portadores de insufici&#234;ncia hep&#225;tica avan&#231;ada foi de 17,6% (21 casos).</p>
    <p>O sexo e os n&#237;veis s&#233;ricos de colesterol e suas fra&#231;&#245;es n&#227;o foram fator de risco significante para o surgimento de doen&#231;a obstrutiva coron&#225;ria. Comprovou-se que esses pacientes com insufici&#234;ncia hep&#225;tica avan&#231;ada apresentavam realmente n&#237;veis baixos de colesterol. Por um lado, para o grupo de pacientes normais, a m&#233;dia e o desvio padr&#227;o para o colesterol total foi de 129,0 &#177; 53,5 mg/dl com mediana de 117,0 mg/dL. Por outro lado, no grupo de coronariopatas, esses valores foram respectivamente de 135,4 &#177; 51,7 mg/dl com mediana de 122,0 mg/dl (P=0,8215; teste de <italic>Mann-Whitney</italic>). Os demais resultados encontram-se na <xref ref-type="table" rid="tab01">Tabela 1</xref>. Na regress&#227;o log&#237;stica multivariada, incluiu-se a idade, o sexo, o IMC e as presen&#231;as de hipertens&#227;o arterial, diabete, tabagismo e etilismo. Por meio dessa primeira an&#225;lise, obtiveram-se valores de P abaixo de 0,20 apenas para idade, sexo, hipertens&#227;o e diabete. Uma nova formula&#231;&#227;o apenas com essas quatro vari&#225;veis mostrou que idade, sexo e diabete foram pouco relevantes para a ocorr&#234;ncia de DAC em hepatopatas graves. Por sua vez, com valor de P de 0,0474, a hipertens&#227;o arterial mostrou-se relevante para a presen&#231;a de DAC. </p>
    <p content-type="asset">
      <table-wrap id="tab01">
        <graphic xlink:href="1678-4170-abc-96-01-0026-00160-gt01.jpg"/></table-wrap>
    </p>
    <p>A equa&#231;&#227;o final ficou assim representada: logit Y = -3,727304 +0,966403 [idade] +1,102597 [sexo] +1,032956 [hipertens&#227;o] +0,990118 [diabete].</p>
    <p>Por fim, n&#227;o houve rela&#231;&#227;o alguma estabelecida entre as causas da insufici&#234;ncia hep&#225;tica avan&#231;ada e o desenvolvimento de doen&#231;a arterial coronariana. Isso significa que nenhuma das etiologias da insufici&#234;ncia hep&#225;tica avan&#231;ada em especial predisp&#245;e ao desenvolvimento de coronariopatia.</p>
    <p>
      <bold>Discuss&#227;o</bold>
    </p>
    <p>A ocorr&#234;ncia de coronariopatia encontrada neste estudo (17,6%) foi equivalente &#224; taxa de 16,2% encontrada por Carey WD e cols., que consideraram apenas pacientes acima de 50 anos, com obstru&#231;&#227;o grave das art&#233;rias coron&#225;rias<sup>5</sup>. A preval&#234;ncia de 5%, resultado dos estudos de Plotkin e cols.<sup>6</sup> sobre pacientes acima de 40 anos com obstru&#231;&#227;o coron&#225;ria significativa, foi muito menor do que a obtida neste estudo. Essa preval&#234;ncia de 17,6% &#233; preocupante porque os riscos de morbidade e mortalidade dos pacientes com doen&#231;a arterial coronariana, uma vez submetidos ao transplante de f&#237;gado, s&#227;o significativamente aumentados, mesmo quando a doen&#231;a arterial coronariana &#233; tratada com medicamentos ou cirurgia antes do transplante de f&#237;gado<sup>8</sup>. </p>
    <p>A idade &#233; sabidamente um fator de risco imut&#225;vel para o desenvolvimento de DAC<sup>1</sup>, de modo que a sua preval&#234;ncia aumenta com a idade. Nos pacientes analisados, a idade n&#227;o se apresentou como um fator de risco para desenvolvimento de DAC. </p>
    <p>Da mesma forma, pertencer ao sexo masculino tamb&#233;m constitui um fator de risco imut&#225;vel para DAC. Por&#233;m, neste trabalho, n&#227;o foi significativa a diferen&#231;a na preval&#234;ncia de coronariopatia em indiv&#237;duos do sexo masculino ou feminino, portadores de insufici&#234;ncia hep&#225;tica avan&#231;ada. Esse fato deve-se possivelmente aos maiores n&#237;veis de estr&#243;geno encontrados em pacientes cirr&#243;ticos<sup>4</sup>.</p>
    <p>O IMC &#233; uma medida da obesidade, que &#233; um fator de risco para DAC, al&#233;m de estar associado a aumento de mortalidade ap&#243;s um eventual transplante de f&#237;gado<sup>10</sup>. Entretanto, nos pacientes deste estudo, n&#227;o houve diferen&#231;a significativa entre a obesidade nos pacientes com ou sem coronariopatia. Da mesma maneira, o tabagismo, conhecido fator de risco para DAC, n&#227;o foi muito diferente nos grupos de pacientes com insufici&#234;ncia hep&#225;tica avan&#231;ada com DAC ou sem DAC.</p>
    <p>O diabete, por sua vez, tamb&#233;m n&#227;o se apresentou como fator de risco para DAC em pacientes com insufici&#234;ncia hep&#225;tica avan&#231;ada. Esse &#233; um resultado inesperado, uma vez que o diabete costuma associar-se a outras comorbidades, como obesidade, hipertens&#227;o arterial e a pr&#243;pria DAC. Sabendo-se que o diabete geralmente se desenvolve com altera&#231;&#245;es micro e macrovasculares e com um maior risco de aterosclerose<sup>11</sup>, seria esperado que o diabete se confirmasse como fator de risco para DAC, mesmo nos pacientes com insufici&#234;ncia hep&#225;tica avan&#231;ada.</p>
    <p>Com rela&#231;&#227;o ao etilismo, sabe-se que a ingest&#227;o moderada de &#225;lcool reduz o risco de aterosclerose por aumentar os n&#237;veis de HDL. Por&#233;m, em quantidades excessivas, o &#225;lcool leva &#224; hipertens&#227;o arterial e a um maior risco de oclus&#227;o arterial<sup>12</sup>. Apesar disso, o etilismo n&#227;o foi confirmado como fator de risco para DAC nos pacientes analisados.</p>
    <p>A hipertens&#227;o arterial &#233; um potente fator de risco cardiovascular, que pode propiciar o desenvolvimento da aterosclerose<sup>13</sup>. Al&#233;m disso, &#233; agravada pelo abuso de &#225;lcool<sup>12</sup> e muitas vezes se associa ao diabete<sup>11</sup>. Como regra geral, s&#227;o encontrados n&#237;veis press&#243;ricos mais baixos nos pacientes cirr&#243;ticos<sup>13,14</sup>.</p>
    <p>Com rela&#231;&#227;o aos n&#237;veis s&#233;ricos de colesterol total, HDL, LDL e triglic&#233;rides, n&#227;o foi encontrada diferen&#231;a significativa entre os grupos de pacientes hepatopatas com ou sem coronariopatia. Devido &#224; doen&#231;a hep&#225;tica avan&#231;ada, esses pacientes apresentam n&#237;veis s&#233;ricos de colesterol reduzidos, decorrentes da perda de fun&#231;&#227;o do f&#237;gado, por&#233;m a hipocolesterolemia seria um fator protetor em rela&#231;&#227;o &#224; DAC. </p>
    <p>As diversas etiologias da hepatopatia, por fim, tamb&#233;m n&#227;o mostraram rela&#231;&#227;o com a predisposi&#231;&#227;o &#224; DAC. Seria esperado que, pelo menos, a etiologia alco&#243;lica se destacasse de alguma forma, seja por seus efeitos ben&#233;ficos ao aumentar o HDL e reduzir o risco cardiovascular, seja por seus efeitos prejudiciais, elevando a press&#227;o arterial e aumentando os riscos de oclus&#227;o arterial<sup>12</sup>. Por&#233;m, o etilismo n&#227;o se mostrou significativamente diferente nos grupos com ou sem coronariopatia.</p>
    <p>Foi utilizada a cinecoronariografia como padr&#227;o-ouro para o diagn&#243;stico de coronariopatia obstrutiva. Tiukinhoy-Laing e cols.<sup>15</sup>, em 2006, tamb&#233;m usaram a cinecoronariografia como padr&#227;o-ouro, em 161 pacientes com idade igual ou maior que 45 anos, em avalia&#231;&#227;o pr&#233;-operat&#243;ria para transplante hep&#225;tico. Constataram alta preval&#234;ncia de fatores de risco para aterosclerose, em que metade dos casos apresentava hipertens&#227;o ou diabete e dois ou mais fatores de risco al&#233;m da idade foram encontrados em um n&#250;mero superior &#224; metade. Encontrou-se preval&#234;ncia de 26% de doen&#231;a ateroscletor&#243;tica moderada ou grave. Nesse grupo, a maioria era de homens, idosos e, frequentemente, portadores de hipertens&#227;o ou diabete, resultado semelhante ao que se encontrou neste estudo.</p>
    <p>Outros autores j&#225; buscaram t&#233;cnicas alternativas e n&#227;o invasivas como, por exemplo, a tomografia computadorizada card&#237;aca. McAvoy e cols.<sup>16</sup>, em 2008, avaliaram 147 pacientes consecutivos no pr&#233;-operat&#243;rio de transplante hep&#225;tico ortot&#243;pico, com aux&#237;lio da tomografia computadorizada card&#237;aca, em busca da calcifica&#231;&#227;o arterial coron&#225;ria. Desse grupo, 46 foram exclu&#237;dos da an&#225;lise em face da n&#227;o informa&#231;&#227;o do escore de c&#225;lcio. Fizeram a compara&#231;&#227;o com v&#225;rios fatores de risco, por meio de an&#225;lise multivariada concluindo que idade, press&#227;o arterial sist&#243;lica, glicemia de jejum, quantidade de componentes da s&#237;ndrome metab&#243;lica e n&#250;mero de vasos envolvidos permaneceram moderadamente associados com calcifica&#231;&#227;o arterial coron&#225;ria. Observe-se que, basicamente, os mesmos fatores foram encontrados no presente estudo.</p>
    <p>
      <bold>Conclus&#227;o</bold>
    </p>
    <p>Com base neste estudo, pode-se concluir que a preval&#234;ncia de doen&#231;a obstrutiva coron&#225;ria &#233; elevada em pacientes com insufici&#234;ncia hep&#225;tica avan&#231;ada em pr&#233;-operat&#243;rio de transplante hep&#225;tico e que, na an&#225;lise multivariada, apenas a hipertens&#227;o arterial foi fator de risco independente com signific&#226;ncia estat&#237;stica para o desenvolvimento de DAC. Por ser a hipertens&#227;o um fator de risco modific&#225;vel, esse achado orienta para a pr&#225;tica de atitudes terap&#234;uticas na tentativa de evitar ou retardar o desenvolvimento da DAC no grupo de pacientes hepatopatas cr&#244;nicos avan&#231;ados. </p>
    <p>
      <bold>Potencial Conflito de Interesses</bold>
    </p>
    <p>Declaro n&#227;o haver conflito de interesses pertinentes.</p>
    <p>
      <bold>Fontes de Financiamento</bold>
    </p>
    <p>O presente estudo n&#227;o teve fontes de financiamento externas.</p>
    <p>
      <bold>Vincula&#231;&#227;o Acad&#234;mica</bold>
    </p>
    <p>N&#227;o h&#225; vincula&#231;&#227;o deste estudo a programas de p&#243;s-gradua&#231;&#227;o.</p>
    <p>
      <fn id="nt" fn-type="corresp">
        <p>Correspond&#234;ncia:</p>
        <p> Moacir Fernandes de Godoy </p>
        <p> Rua Garabed Karabashian, 570 - Mansur Daud </p>
        <p> 15070-600 - S&#227;o Jos&#233; do Rio Preto, SP - Brasil </p>
        <p> E-mail: </p>
        <p><email xlink:href="moacirgodoy@cardiol.br">moacirgodoy@cardiol.br</email>, </p>
        <p>
          <email xlink:href="mfgodoy@netsite.com.br">mfgodoy@netsite.com.br</email>
        </p>
      </fn>
    </p>
    <p> Artigo recebido em 11/07/09 </p>
    <p> revisado recebido em 16/06/10 </p>
    <p> aceito em 17/06/10</p>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation>1. Braunwald E. Heart disease: a textbook of cardiovascular medicine. 5th ed. Philadelphia: Saunders; 1997. p. 1105-25.</mixed-citation>
        <element-citation publication-type="book">
          <source>Heart disease: a textbook of cardiovascular medicine</source>
          <date>
            <year>1997</year>
          </date>
          <person-group person-group-type="author">
            <name>
              <surname>Braunwald</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B2">
        <mixed-citation>2. D'Arienzo A, Manguso F, Scaglione G, Vicinanza G, Bennato R, Mazzacca G. Prognostic value of progressive decrease in serum cholesterol in predicting survival in child-pugh C viral cirrhosis. Scandinavian J Gastroenterol.1998; 33 (11): 1213-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prognostic value of progressive decrease in serum cholesterol in predicting survival in child-pugh C viral cirrhosis</article-title>
          <source>Scandinavian J Gastroenterol</source>
          <date>
            <year>1998</year>
          </date>
          <fpage>1213</fpage>
          <lpage>8</lpage>
          <issue>11</issue>
          <volume>33</volume>
          <person-group person-group-type="author">
            <name>
              <surname>D'Arienzo</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Manguso</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Scaglione</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Vicinanza</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Bennato</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Mazzacca</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B3">
        <mixed-citation>3. Pruthi J, Medkiff KA, Esrason KT, Donovan JA, Yoshida EM, Erb SR, et al. Analysis of causes of death in liver transplant recipients who survived more than 3 years. Liver Transpl. 2001; 7 (9): 811-5.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Analysis of causes of death in liver transplant recipients who survived more than 3 years</article-title>
          <source>Liver Transpl</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>811</fpage>
          <lpage>5</lpage>
          <issue>9</issue>
          <volume>7</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Pruthi</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Medkiff</surname>
              <given-names>KA</given-names>
            </name>
            <name>
              <surname>Esrason</surname>
              <given-names>KT</given-names>
            </name>
            <name>
              <surname>Donovan</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Yoshida</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Erb</surname>
              <given-names>SR</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B4">
        <mixed-citation>4. Keeffe BG, Valantine H, Keeffe EB. Detection and treatment of coronary artery disease in liver transplant candidates. Liver Transpl. 2001; 7 (9): 755-61.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Detection and treatment of coronary artery disease in liver transplant candidates</article-title>
          <source>Liver Transpl</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>755</fpage>
          <lpage>61</lpage>
          <issue>9</issue>
          <volume>7</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Keeffe</surname>
              <given-names>BG</given-names>
            </name>
            <name>
              <surname>Valantine</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Keeffe</surname>
              <given-names>EB</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B5">
        <mixed-citation>5. Carey WD, Dumot JA, Pimentel RR, Barnes DS, Hobbs RE, Henderson JM, et al. The prevalence of coronary artery disease in liver transplant candidates over age 50. Transplantation. 1995; 59 (6): 859-64.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The prevalence of coronary artery disease in liver transplant candidates over age 50</article-title>
          <source>Transplantation</source>
          <date>
            <year>1995</year>
          </date>
          <fpage>859</fpage>
          <lpage>64</lpage>
          <issue>6</issue>
          <volume>59</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Carey</surname>
              <given-names>WD</given-names>
            </name>
            <name>
              <surname>Dumot</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Pimentel</surname>
              <given-names>RR</given-names>
            </name>
            <name>
              <surname>Barnes</surname>
              <given-names>DS</given-names>
            </name>
            <name>
              <surname>Hobbs</surname>
              <given-names>RE</given-names>
            </name>
            <name>
              <surname>Henderson</surname>
              <given-names>JM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B6">
        <mixed-citation>6. Plotkin JS, Scott VL, Pinna A, Dobsch BP, De Wolf AM, Kang Y. Morbidity and mortality in patients with coronary artery disease undergoing orthotopic liver transplantation. Liver Transpl Surg. 1996; 2 (6): 426-30.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Morbidity and mortality in patients with coronary artery disease undergoing orthotopic liver transplantation</article-title>
          <source>Liver Transpl Surg</source>
          <date>
            <year>1996</year>
          </date>
          <fpage>426</fpage>
          <lpage>30</lpage>
          <issue>6</issue>
          <volume>2</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Plotkin</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Scott</surname>
              <given-names>VL</given-names>
            </name>
            <name>
              <surname>Pinna</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Dobsch</surname>
              <given-names>BP</given-names>
            </name>
            <name>
              <surname>De Wolf</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Kang</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B7">
        <mixed-citation>7. Guckelberger O, Mutzke F, Glanemann M, Neumann UP, Jonas S, Neuhaus R, et al. Validation of cardiovascular risk scores in a liver transplant population. Liver Transpl. 2006 (12): 394-401.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Validation of cardiovascular risk scores in a liver transplant population</article-title>
          <source>Liver Transpl.</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>394</fpage>
          <lpage>401</lpage>
          <issue>12</issue>
          <person-group person-group-type="author">
            <name>
              <surname>Guckelberger</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Mutzke</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Glanemann</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Neumann</surname>
              <given-names>UP</given-names>
            </name>
            <name>
              <surname>Jonas</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Neuhaus</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B8">
        <mixed-citation>8. Benedetti E, Massad MG, Chami Y, Wiley T, Layden TJ. Is the presence of surgically treatable coronary artery disease a contraindication to liver transplantation? Clin Transplant. 1999; 13 (1 Pt 1): 59-61.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Is the presence of surgically treatable coronary artery disease a contraindication to liver transplantation</article-title>
          <source>Clin Transplant</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>59</fpage>
          <lpage>61</lpage>
          <issue>1 Pt 1</issue>
          <volume>13</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Benedetti</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Massad</surname>
              <given-names>MG</given-names>
            </name>
            <name>
              <surname>Chami</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Wiley</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Layden</surname>
              <given-names>TJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B9">
        <mixed-citation>9. Appleton CP, Hurst RT. Reducing coronary artery disease events in liver transplant patients: moving toward identifying the vulnerable patient. Liver Transpl. 2008; 14 (12): 1691-3.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Reducing coronary artery disease events in liver transplant patients: moving toward identifying the vulnerable patient</article-title>
          <source>Liver Transpl</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>1691</fpage>
          <lpage>3</lpage>
          <issue>12</issue>
          <volume>14</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Appleton</surname>
              <given-names>CP</given-names>
            </name>
            <name>
              <surname>Hurst</surname>
              <given-names>RT</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B10">
        <mixed-citation>10. Nair S, Verma S, Thuluvath PJ. Obesity and its effect on survival in patients undergoing orthotopic liver transplantation in the United States. Hepatology. 2002; 35 (1): 105-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Obesity and its effect on survival in patients undergoing orthotopic liver transplantation in the United States</article-title>
          <source>Hepatology</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>105</fpage>
          <lpage>9</lpage>
          <issue>1</issue>
          <volume>35</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Nair</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Verma</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Thuluvath</surname>
              <given-names>PJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B11">
        <mixed-citation>11. Thuluvath PJ. When is diabetes mellitus a relative or absolute contraindication to liver transplantation? Liver Transpl. 2005; 11 (Suppl 2): S25-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>When is diabetes mellitus a relative or absolute contraindication to liver transplantation</article-title>
          <source>Liver Transpl</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>S25</fpage>
          <lpage>9</lpage>
          <volume>11</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Thuluvath</surname>
              <given-names>PJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B12">
        <mixed-citation>12. da Luz PL, Coimbra SR. Alcohol and atherosclerosis. An Acad Bras Cir. 2001; 73 (1): 51-5.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Alcohol and atherosclerosis</article-title>
          <source>An Acad Bras Cir</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>51</fpage>
          <lpage>5</lpage>
          <issue>1</issue>
          <volume>73</volume>
          <person-group person-group-type="author">
            <name>
              <surname>da Luz</surname>
              <given-names>PL</given-names>
            </name>
            <name>
              <surname>Coimbra</surname>
              <given-names>SR</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B13">
        <mixed-citation>13. Tedgui A, Mallat Z. Hypertension? A novel regulator of adaptive immunity in atherosclerosis? Hipertension. 2004; 44 (3): 257-82.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Hypertension: A novel regulator of adaptive immunity in atherosclerosis?</article-title>
          <source>Hipertension</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>257</fpage>
          <lpage>82</lpage>
          <issue>3</issue>
          <volume>44</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Tedgui</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Mallat</surname>
              <given-names>Z</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B14">
        <mixed-citation>14. Kawakami M, Koda M, Murawaki Y. The prevalence of atherosclerosis in cirrhotic patients: assessment of two aspects of atherosis and sclerosis Hepatol Res. 2007; 37 (2): 152-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The prevalence of atherosclerosis in cirrhotic patients: assessment of two aspects of atherosis and sclerosis Hepatol</article-title>
          <source>Res</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>152</fpage>
          <lpage>7</lpage>
          <issue>2</issue>
          <volume>37</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Kawakami</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Koda</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Murawaki</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B15">
        <mixed-citation>15. Tiukinhoy-Laing SD, Rossi JS, Bayram M, De Luca L, Gafoor S, Blei A, et al. Cardiac hemodynamic and coronary angiographic characteristics of patients being evaluated for liver transplantation. Am J Cardiol. 2006; 98 (2): 178-81.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Cardiac hemodynamic and coronary angiographic characteristics of patients being evaluated for liver transplantation</article-title>
          <source>Am J Cardiol</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>178</fpage>
          <lpage>81</lpage>
          <issue>2</issue>
          <volume>98</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Tiukinhoy-Laing</surname>
              <given-names>SD</given-names>
            </name>
            <name>
              <surname>Rossi</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Bayram</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>De Luca</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Gafoor</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Blei</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B16">
        <mixed-citation>16. McAvoy NC, Kochar N, McKillop G, Newby DE, Hayes PC. Prevalence of coronary artery calcification in patients undergoing assessment for orthotopic liver transplantation. Liver Transpl. 2008; 14 (12): 1725-31.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prevalence of coronary artery calcification in patients undergoing assessment for orthotopic liver transplantation</article-title>
          <source>Liver Transpl</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>1725</fpage>
          <lpage>31</lpage>
          <issue>12</issue>
          <volume>14</volume>
          <person-group person-group-type="author">
            <name>
              <surname>McAvoy</surname>
              <given-names>NC</given-names>
            </name>
            <name>
              <surname>Kochar</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>McKillop</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Newby</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Hayes</surname>
              <given-names>PC</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="TRes" xml:lang="es">
    <front-stub>
      <article-categories/>
      <title-group>
        <article-title xml:lang="es">Enfermedad coronaria obstructiva en hepat&#243;patas cr&#243;nicos que aguardan trasplante hep&#225;tico</article-title>
      </title-group>
      <abstract xml:lang="es">
        <p>FUNDAMENTO: La insuficiencia hep&#225;tica avanzada (IHA) generalmente cursa con hipocolesterolemia. A pesar de eso, una parcela de los pacientes con IHA desarrolla coronariopat&#237;a obstructiva de grado importante con consecuente aumento de riesgo o incluso contraindicaci&#243;n para trasplante hep&#225;tico. OBJETIVOS: Analizar la contribuci&#243;n de los factores de riesgo cl&#225;sicos para la enfermedad arterial coronaria (EAC) en pacientes portadores de IHA con y sin coronariopat&#237;a obstructiva. M&#201;TODOS: Evaluaci&#243;n de los factores de riesgo para EAC en 119 pacientes, en un servicio de referencia para trasplante hep&#225;tico, con las siguientes caracter&#237;sticas: m&#225;s de 40 a&#241;os de edad, portadores de IHA y sometidos a cinecoronariograf&#237;a. RESULTADOS: Coronariopat&#237;a obstructiva fue detectada en 21 (17,6%) de los casos. Estos pacientes presentaban realmente niveles bajos de colesterol, siendo de 129,0&#177;53,5mg/dL con mediana de 117,0mg/dL en los hepat&#243;patas con coronarias normales y 135,4&#177;51,7mg/dL con mediana de 122,0mg/dL en los hepat&#243;patas con coronariopat&#237;a obstructiva (P=0,8215). En la regresi&#243;n log&#237;stica multivariada, la edad, el sexo, el &#237;ndice de masa corporal, as&#237; como las presencias de diabetes, de tabaquismo y de etilismo no tuvieron significancia estad&#237;stica aislada en la diferenciaci&#243;n entre los grupos. Tambi&#233;n no hubo asociaci&#243;n con la etiolog&#237;a de la IHA. A su vez, la hipertensi&#243;n arterial se mostr&#243; relevante en la asociaci&#243;n con EAC (P=0,0474). CONCLUSI&#211;N: S&#243;lo la hipertensi&#243;n arterial fue factor de riesgo con significancia estad&#237;stica para el desarrollo de EAC en pacientes con IHA aguardando trasplante hep&#225;tico. Por ser un factor de riesgo cambiable, este hallazgo orienta hacia una pr&#225;ctica de actitudes terap&#233;uticas en la tentativa de evitarse o retardar el desarrollo de la EAC en estos pacientes.</p>
      </abstract>
      <kwd-group xml:lang="es">
        <kwd>Enfermedad de la arteria coronaria</kwd>
        <kwd>hepatopat&#237;as</kwd>
        <kwd>trasplante de h&#237;gado</kwd>
        <kwd>factores de riesgo</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>ART&#205;CULO ORIGINAL</p>
      <p> CORONARIOPATIA CR&#212;NICA</p>
      <p>
        <fn id="nota_1-body2">
          <label>
            <bold>Enfermedad coronaria obstructiva en hepat&#243;patas cr&#243;nicos que aguardan trasplante hep&#225;tico</bold>
          </label>
          <p>
            <bold>Moacir Fernandes de Godoy<sup>I,II</sup>; Patricia de Oliveira Roveri<sup>I</sup>; Marcio Antonio dos Santos<sup>II</sup>; Flavio Correa Pivatelli<sup>II</sup>; Rita de C&#225;ssia Martins Alves da Silva<sup>II</sup>; Renato Ferreira da Silva<sup>II</sup></bold>
          </p>
        </fn>
      </p>
      <p><sup>I</sup>Faculdade de Medicina de S&#227;o Jos&#233; do Rio Preto (FAMERP), S&#227;o Jos&#233; do Rio Preto, SP - Brasil</p>
      <p><sup>II</sup>Funda&#231;&#227;o Faculdade Regional de Medicina (FUNFARME), S&#227;o Jos&#233; do Rio Preto, SP - Brasil</p>
      <p>Correspondencia</p>
      <p>
        <bold>RESUMEN</bold>
      </p>
      <p><bold>FUNDAMENTO:</bold> La insuficiencia hep&#225;tica avanzada (IHA) generalmente cursa con hipocolesterolemia. A pesar de eso, una parcela de los pacientes con IHA desarrolla coronariopat&#237;a obstructiva de grado importante con consecuente aumento de riesgo o incluso contraindicaci&#243;n para trasplante hep&#225;tico.</p>
      <p><bold>OBJETIVOS:</bold> Analizar la contribuci&#243;n de los factores de riesgo cl&#225;sicos para la enfermedad arterial coronaria (EAC) en pacientes portadores de IHA con y sin coronariopat&#237;a obstructiva.</p>
      <p><bold>M&#201;TODOS:</bold> Evaluaci&#243;n de los factores de riesgo para EAC en 119 pacientes, en un servicio de referencia para trasplante hep&#225;tico, con las siguientes caracter&#237;sticas: m&#225;s de 40 a&#241;os de edad, portadores de IHA y sometidos a cinecoronariograf&#237;a.</p>
      <p><bold>RESULTADOS:</bold> Coronariopat&#237;a obstructiva fue detectada en 21 (17,6%) de los casos. Estos pacientes presentaban realmente niveles bajos de colesterol, siendo de 129,0&#177;53,5mg/dL con mediana de 117,0mg/dL en los hepat&#243;patas con coronarias normales y 135,4&#177;51,7mg/dL con mediana de 122,0mg/dL en los hepat&#243;patas con coronariopat&#237;a obstructiva (P=0,8215). En la regresi&#243;n log&#237;stica multivariada, la edad, el sexo, el &#237;ndice de masa corporal, as&#237; como las presencias de diabetes, de tabaquismo y de etilismo no tuvieron significancia estad&#237;stica aislada en la diferenciaci&#243;n entre los grupos. Tambi&#233;n no hubo asociaci&#243;n con la etiolog&#237;a de la IHA. A su vez, la hipertensi&#243;n arterial se mostr&#243; relevante en la asociaci&#243;n con EAC (P=0,0474).</p>
      <p><bold>CONCLUSI&#211;N:</bold> S&#243;lo la hipertensi&#243;n arterial fue factor de riesgo con significancia estad&#237;stica para el desarrollo de EAC en pacientes con IHA aguardando trasplante hep&#225;tico. Por ser un factor de riesgo cambiable, este hallazgo orienta hacia una pr&#225;ctica de actitudes terap&#233;uticas en la tentativa de evitarse o retardar el desarrollo de la EAC en estos pacientes.</p>
      <p><bold>Palabras clave:</bold> Enfermedad de la arteria coronaria; hepatopat&#237;as, trasplante de h&#237;gado, factores de riesgo.</p>
      <p>
        <bold>Introducci&#243;n</bold>
      </p>
      <p>La enfermedad arterial coronaria (EAC) es la causa m&#225;s com&#250;n de isquemia del miocardio, pudiendo culminar en infarto del miocardio, adem&#225;s de ser la principal causa de muerte en la civilizaci&#243;n occidental. La EAC se caracteriza por la formaci&#243;n de dep&#243;sitos de grasa (ateromas) en la pared de las arterias, obstruyendo gradualmente su luz, principalmente en las de medio calibre, entre las que est&#225;n las coronarias<sup>1</sup>.</p>
      <p>Los factores de riesgo para EAC incluyen hipercolesterolemia, con aumento de los niveles de la lipoprote&#237;na de baja densidad (LDL) plasm&#225;tica, tabaquismo, hipertensi&#243;n arterial, diabetes, obesidad, sedentarismo, niveles s&#233;ricos de triglic&#233;ridos aumentados, predisposici&#243;n gen&#233;tica, edad y sexo masculino, entre los que se destaca la hipercolesterolem&#237;a<sup>1</sup>.</p>
      <p>Los altos niveles s&#233;ricos de LDL tambi&#233;n son capaces de aumentar la capacidad de adhesi&#243;n de los monocitos circulantes, que se adhieren a las c&#233;lulas endoteliales lesionadas, son atra&#237;dos por quimiotax&#237;a para la regi&#243;n subendotelial, se acumulan y se vuelven macr&#243;fagos, que fagocitan LDL hasta convertirse en "c&#233;lulas espumosas" o <italic>foam cells</italic>. Esos macr&#243;fagos son, a&#250;n, responsables de la liberaci&#243;n de diversos factores de crecimiento, que act&#250;an en las c&#233;lulas musculares lisas y fibroblastos, formando m&#225;s tejido conectivo y originando placas fibrosas<sup>1</sup>.</p>
      <p>Una tercera acci&#243;n de los elevados niveles de LDL se produce sobre las plaquetas. Tras la lesi&#243;n endotelial, como resultado de la retracci&#243;n de las c&#233;lulas endoteliales, las plaquetas pueden entrar en contacto con las c&#233;lulas espumosas, lo que culmina con la adhesi&#243;n, la agregaci&#243;n y, finalmente, la formaci&#243;n de un trombo mural, que ocluye la luz de la arteria. Este ciclo todo que lleva a la formaci&#243;n de las placas ateromatosas puede repetirse continuamente, propiciando oclusi&#243;n progresiva del vaso<sup>1</sup>.</p>
      <p>La insuficiencia hep&#225;tica, en contrapartida, es una enfermedad que se caracteriza por una severa p&#233;rdida de la funci&#243;n del h&#237;gado, debido a alg&#250;n tipo de disturbio como hepatitis virales, cirrosis y hepatopat&#237;a medicamentosa o alcoh&#243;lica<sup>2</sup>.</p>
      <p>El h&#237;gado es el local m&#225;s activo de metabolismo del colesterol y, en casos de insuficiencia hep&#225;tica avanzada, la p&#233;rdida de funci&#243;n de este &#243;rgano lleva a la reducci&#243;n de los niveles plasm&#225;ticos de colesterol.</p>
      <p>La mortalidad de la insuficiencia hep&#225;tica var&#237;a entre el 40% y el 80%, y el trasplante de h&#237;gado consiste en la &#250;nica alternativa terap&#233;utica capaz de proporcionar al paciente portador de esta enfermedad una mejora significativa de la sobrevida<sup>3</sup>. El trasplante es el tratamiento establecido para enfermedades avanzadas del h&#237;gado e insuficiencia hep&#225;tica, de modo que, en los Estados Unidos, se llevan a cabo 4.000 trasplantes de h&#237;gado anualmente<sup>4</sup>. </p>
      <p>La cirrosis hep&#225;tica puede ser de origen alcoh&#243;lica. Se sabe que la ingesta moderada de alcohol tiene efecto ben&#233;fico sobre la aterosclerosis, por elevar los niveles de lipoprote&#237;na de alta densidad (HDL) plasm&#225;tica, lo que ser&#237;a m&#225;s una contraindicaci&#243;n para la ocurrencia de enfermedad arterial coronaria en pacientes con insuficiencia hep&#225;tica. La funci&#243;n del HDL consiste en hacer el transporte reverso del colesterol, llev&#225;ndolo de los tejidos al h&#237;gado, donde se metaboliza y se excreta<sup>1</sup>. Eso explica porque los niveles adecuados de HDL reducen los riesgos para aterosclerosis.</p>
      <p>Con base en estos datos, no ser&#237;a esperado encontrar aterosclerosis en pacientes con insuficiencia hep&#225;tica a espera de trasplante de h&#237;gado. Sin embargo, se encontr&#243; una prevalencia general de un 16,2% de enfermedad arterial coronaria severa (obstrucci&#243;n mayor que el 70% de las coronarias) en pacientes superior a 50 a&#241;os en evaluaci&#243;n preoperatoria para trasplante de h&#237;gado, diagnosticada por cateterismo<sup>5</sup>. Plotkin et al<sup>6</sup> encontraron, con base en cateterismo card&#237;aco y en ecocardiograma de estr&#233;s con dobutamina, el 5% de enfermedad arterial coronaria significativa (con obstrucci&#243;n del 70% o m&#225;s de las coronarias) en pacientes con m&#225;s de 40 a&#241;os<sup>6</sup>.</p>
      <p>Se sabe que la mortalidad quir&#250;rgica de hepat&#243;patas cr&#243;nicos sometidos a trasplante hep&#225;tico es mayor en la presencia de coronariopat&#237;a obstructiva, y esta mortalidad por enfermedad cardiovascular continua a expresarse en el postoperatorio tard&#237;o de los trasplantados<sup>7</sup>.</p>
      <p>La enfermedad arterial coronaria diagnosticada en pacientes en evaluaci&#243;n preoperatoria para trasplante de h&#237;gado, a pesar de ser muchas veces considerada como una contraindicaci&#243;n absoluta, no necesita necesariamente ser encarada como tal, sin embargo se tiene en cuenta que los riesgos de morbilidad y mortalidad en trasplantes de h&#237;gado en pacientes con enfermedad arterial coronaria son aumentados significativamente, y se elevan igualmente en los casos en que el trasplante se lleva a cabo tras tratamiento medicamentoso o quir&#250;rgico de la enfermedad arterial coronaria<sup>8</sup>. Sin embargo, no hay a&#250;n definici&#243;n respeto a que factor de riesgo que mejor predice la presencia de coronariopat&#237;a obstructiva en pacientes con insuficiencia hep&#225;tica avanzada<sup>9</sup>.</p>
      <p>As&#237;, el objetivo del presente estudio fue analizar a pacientes con insuficiencia hep&#225;tica avanzada con y sin diagn&#243;stico de enfermedad arterial coronaria asociada, en b&#250;squeda de los factores de riesgo que podr&#237;an justificar el desarrollo de las obstrucciones.</p>
      <p>
        <bold>Materiales y m&#233;todos</bold>
      </p>
      <p>Se revisaron 119 prontuarios de pacientes con m&#225;s de 40 a&#241;os, portadores de insuficiencia hep&#225;tica avanzada (IHA), que aguardaban en una <italic>fila de trasplante</italic> de h&#237;gado y que hab&#237;an sido sometidos a cateterismo card&#237;aco como parte de los procedimientos de evaluaci&#243;n cl&#237;nica preoperatoria. El protocolo de evaluaci&#243;n cl&#237;nica pretrasplante hep&#225;tico en nuestro servicio inclu&#237;a la realizaci&#243;n de cateterismo cardiaco en todos los pacientes con m&#225;s de 40 anos, una vez que la prueba de esfuerzo muchas veces es inviable en este grupo, adem&#225;s de esto, muy frecuentemente est&#225;n en uso de vasodilatadores y betabloqueantes. </p>
      <p>Para calcularse la frecuencia con que la coronariopat&#237;a puede producirse, se tomaron en consideraci&#243;n solamente a los pacientes con obstrucci&#243;n coronaria con el 50% o m&#225;s de la luz de una rama principal comprometida como m&#237;nimo.</p>
      <p>En el an&#225;lisis estad&#237;stico, las variables cuantitativas continuas con distribuci&#243;n gaussiana se estudiaron con auxilio de la prueba <italic>t</italic> de <italic>Student</italic>, mientras que las cualitativas nominales (o ordinales) o las cuantitativas sin distribuci&#243;n gaussiana se estudiaron con auxilio de la prueba exacto de <italic>Fisher</italic> o prueba de <italic>Mann-Whitney</italic>. La evaluaci&#243;n se complement&#243; con una prueba de regresi&#243;n log&#237;stica m&#250;ltiple.</p>
      <p>Los niveles de cohorte utilizados fueron: colesterol total superior a 200mg/dl, HDL abajo de 40mg/dl, LDL superior a 130mg/dl y triglic&#233;ridos superior a 150mg/dl. Se consideraron como hipertensos a los pacientes con presi&#243;n arterial sist&#243;lica de 140mmHg o mayor; o con presi&#243;n arterial diast&#243;lica de 90mmHg o mayor; o, entonces, en uso de medicaci&#243;n hipotensora. Se definieron como diab&#233;ticos a los pacientes con niveles de glucemia superiores a 126mg/dL o en uso de hipoglucemiantes orales o insulina. Se consideraron como fumadores a los pacientes que fumaban cualquier cantidad de cigarrillos o que hab&#237;an abandonado hasta menos de un a&#241;o antes de la cinecoronariograf&#237;a. Fueron considerados etilistas los que consum&#237;an m&#225;s que dos dosis de alcohol al d&#237;a. Para la utilizaci&#243;n en la regresi&#243;n log&#237;stica, la edad se consider&#243; hasta 55 a&#241;os (0) y m&#225;s que 55 a&#241;os (1); el IMC fue considerado hasta 29,9 kg/m<sup>2</sup> (0) y 30 o m&#225;s kg/m<sup>2</sup> (1). Los valores de l&#237;pidos no se incluyeron en la regresi&#243;n log&#237;stica, ya que como regla general estaban frecuentemente bien debajo de los l&#237;mites m&#225;ximos de la normalidad.</p>
      <p>Para analizar las causas de insuficiencia hep&#225;tica avanzada, los pacientes se dividieron en cuatro grupos: portadores de virus (incluyendo virus B, virus C o ambos), etilistas, pacientes con asociaci&#243;n de virus y alcohol y pacientes con insuficiencia hep&#225;tica idiop&#225;tica o criptog&#233;nica. Se admiti&#243; error alfa del 5%, y se tom&#243; en consideraci&#243;n significantes valores de P <underline>&lt;</underline> 0,05. La investigaci&#243;n fue aprobada por el Comit&#233; de &#201;tica de la Instituci&#243;n.</p>
      <p>
        <bold>Resultados</bold>
      </p>
      <p>La ocurrencia de coronariopat&#237;a en los 119 pacientes con edad superior a 40 a&#241;os y portadores de insuficiencia hep&#225;tica avanzada fue del 17,6% (21 casos). </p>
      <p>El sexo y los niveles s&#233;ricos de colesterol y sus fracciones no fueron factor de riesgo significante para la presencia de enfermedad obstructiva coronaria. Se comprob&#243; que esos pacientes con insuficiencia hep&#225;tica avanzada presentaban realmente niveles bajos de colesterol. Por una parte, para el grupo de pacientes normales, la media y la desviaci&#243;n est&#225;ndar para el colesterol total fue de 129,0&#177;53,5 mg/dL con mediana de 117,0 mg/dL. Por otra parte, en el grupo de coronari&#243;patas, estos valores fueron respectivamente de 135,4&#177;51,7 mg/dL con mediana de 122,0 mg/dL (P=0,8215; prueba de <italic>Mann-Whitney</italic>). Los dem&#225;s resultados se encuentran en la <xref ref-type="table" rid="es_a06tab01-body2">Tabla 1</xref>. En la regresi&#243;n log&#237;stica multivariada, se incluy&#243; la edad, el sexo, el IMC y las presencias de hipertensi&#243;n arterial, diabetes, tabaquismo y etilismo. Por medio de ese primero an&#225;lisis, se obtuvieron valores de P abajo de 0,20 solamente para edad, sexo, hipertensi&#243;n y diabetes. Una nueva formulaci&#243;n solamente con estas cuatro variables mostr&#243; que edad, sexo y diabetes fueron poco relevantes para la ocurrencia de EAC en hepat&#243;patas severos. A su vez, con valor de P de 0,0474, la hipertensi&#243;n arterial se hall&#243; relevante para la presencia de EAC. </p>
      <p content-type="asset">
        <table-wrap id="es_a06tab01-body2">
          <graphic xlink:href="1678-4170-abc-96-01-0026-00160-gt01-es.jpg"/></table-wrap>
      </p>
      <p>Edad (media y desviaci&#243;n est&#225;ndar, en a&#241;o); IMC (media y desviaci&#243;n est&#225;ndar en kg/m<sup>2</sup>; hipertensi&#243;n, diabetes, tabaco y etilismo en cantidad total de casos y porcentaje; colesterol total, HDL colesterol, LDL colesterol y triglic&#233;ridos en mg/dL.</p>
      <p>La ecuaci&#243;n final qued&#243; as&#237; representada: logit Y = -3,727304 + 0,966403 [edad] + 1,102597 [sexo] + 1,032956 [hipertensi&#243;n] + 0,990118 [diabetes].</p>
      <p>Por fin, no hubo relaci&#243;n alguna establecida entre las causas de la insuficiencia hep&#225;tica avanzada y el desarrollo de enfermedad arterial coronaria. Esto significa que ninguna de las etiolog&#237;as de la insuficiencia hep&#225;tica avanzada en especial predispone al desarrollo de coronariopat&#237;a.</p>
      <p>
        <bold>Discusi&#243;n</bold>
      </p>
      <p>La ocurrencia de coronariopat&#237;a encontrada en este estudio (17,6%) fue equivalente a la tasa de un 16,2% encontrada por Carey WD et al., que consideraron solamente a pacientes con edad superior a 50 a&#241;os, con obstrucci&#243;n severa de las arterias coronarias<sup>5</sup>. La prevalencia del 5%, resultado de los estudios de Plotkin et al<sup>6</sup> sobre pacientes con m&#225;s de 40 a&#241;os con obstrucci&#243;n coronaria significativa, fue mucho menor que la obtenida en este estudio. Esta prevalencia de un 17,6% es preocupante porque los riesgos de morbilidad y mortalidad de los pacientes con enfermedad arterial coronaria, una vez sometidos al trasplante de h&#237;gado, son significativamente aumentados, aun cuando la enfermedad arterial coronaria es tratada con medicamentos o cirug&#237;a antes del trasplante de h&#237;gado.<sup>8</sup></p>
      <p>La edad es sabidamente un factor de riesgo inmutable para el desarrollo de EAC<sup>1</sup>, de modo que su prevalencia aumenta con la edad. En los pacientes analizados, la edad no se present&#243; como un factor de riesgo para desarrollo de EAC. </p>
      <p>De igual manera, pertenecer al sexo masculino tambi&#233;n constituye un factor de riesgo inmutable para EAC. Sin embargo, en este trabajo, no fue significativa la diferencia en la prevalencia de coronariopat&#237;a en individuos del sexo masculino o femenino, portadores de insuficiencia hep&#225;tica avanzada. Este hecho se debe posiblemente a los mayores niveles de estr&#243;geno encontrados en pacientes cirr&#243;ticos<sup>4</sup>.</p>
      <p>El IMC es una medici&#243;n de la obesidad, que es un factor de riesgo para EAC, adem&#225;s de estar asociado a aumento de mortalidad tras un eventual trasplante de h&#237;gado<sup>10</sup>. Sin embargo, en los pacientes de este estudio, no hubo diferencia significativa entre la obesidad en los pacientes con o sin coronariopat&#237;a. De igual manera, el tabaquismo, conocido factor de riesgo para EAC, no fue mucho diferente en los grupos de pacientes con insuficiencia hep&#225;tica avanzada con EAC o sin EAC.</p>
      <p>La diabetes, a su vez, tambi&#233;n no se present&#243; como factor de riesgo para EAC en pacientes con insuficiencia hep&#225;tica avanzada. Este es un resultado inesperado, una vez que la diabetes suele asociarse a otras comorbilidades, como obesidad, hipertensi&#243;n arterial y la propia EAC. Sabi&#233;ndose que el diabetes generalmente se desarrolla con alteraciones micro y macrovasculares y con un mayor riesgo de aterosclerosis<sup>11</sup>, ser&#237;a esperado que el diabetes se confirmara como factor de riesgo para EAC, aun en los pacientes con insuficiencia hep&#225;tica avanzada.</p>
      <p>Con relaci&#243;n al etilismo, se sabe que la ingesta moderada de alcohol reduce el riesgo de aterosclerosis por aumentar los niveles de HDL. Sin embargo, en cantidades excesivas, el alcohol lleva a la hipertensi&#243;n arterial y a un mayor riesgo de oclusi&#243;n arterial<sup>12</sup>. A pesar de esto, el etilismo no se confirm&#243; como factor de riesgo para EAC en los pacientes analizados.</p>
      <p>La hipertensi&#243;n arterial es un potente factor de riesgo cardiovascular, que puede propiciar el desarrollo de la aterosclerosis<sup>13</sup>. Adem&#225;s de esto, se agrava por el abuso de alcohol<sup>12</sup> y muchas veces est&#225; asociada a la diabetes<sup>11</sup>. Como regla general, son encontrados niveles de presi&#243;n m&#225;s bajos en los pacientes cirr&#243;ticos<sup>13,14</sup>.</p>
      <p>Con relaci&#243;n a los niveles s&#233;ricos de colesterol total, HDL, LDL y triglic&#233;ridos, no se encontr&#243; diferencia significativa entre los grupos de pacientes hepat&#243;patas con o sin coronariopat&#237;a. Debido a la enfermedad hep&#225;tica avanzada, estos pacientes presentan niveles s&#233;ricos de colesterol reducidos, resultantes de la p&#233;rdida de funci&#243;n del h&#237;gado, sin embargo, la hipocolesterolemia ser&#237;a un factor protector en relaci&#243;n a la EAC. </p>
      <p>Las diversas etiolog&#237;as de la hepatopat&#237;a, por fin, tambi&#233;n no mostraron relaci&#243;n con la predisposici&#243;n a la EAC. Se esperar&#237;a que, al menos, la etiolog&#237;a alcoh&#243;lica se destacara de alguna forma, ya sea por sus efectos ben&#233;ficos al aumentar el HDL y reducir el riesgo cardiovascular, ya sea por sus efectos perjudiciales, elevando la presi&#243;n arterial y aumentando los riesgos de oclusi&#243;n arterial<sup>12</sup>. Sin embargo, el etilismo no se mostr&#243; significativamente diferente en los grupos con o sin coronariopat&#237;a.</p>
      <p>Se utiliz&#243; la cinecoronariograf&#237;a como patr&#243;n-oro para el diagn&#243;stico de coronariopat&#237;a obstructiva. Tiukinhoy-Laing et al<sup>15</sup>, en 2006, tambi&#233;n usaron la cinecoronariograf&#237;a como est&#225;ndar-oro, en 161 pacientes con edad igual o mayor que 45 a&#241;os, en evaluaci&#243;n pre-operatoria para trasplante hep&#225;tico. Constataron alta prevalencia de factores de riesgo para aterosclerosis, en que mitad de los casos presentaba hipertensi&#243;n o diabetes y dos o m&#225;s factores de riesgo adem&#225;s de la edad se encontraron en un n&#250;mero superior a la mitad. Se encontr&#243; prevalencia del 26% de enfermedad ateroscletor&#243;tica moderada o severa. En ese grupo, la mayor&#237;a era de varones, adultos mayores y, frecuentemente, portadores de hipertensi&#243;n o diabetes, resultado similar al que se encontr&#243; en este estudio.</p>
      <p>Otros autores ya buscaron t&#233;cnicas alternativas y no invasivas como, por ejemplo, la Tomograf&#237;a Computarizada Card&#237;aca. McAvoy et al<sup>16</sup> en 2008, evaluaron a 147 pacientes consecutivos en el preoperatorio de trasplante hep&#225;tico ortot&#243;pico, con auxilio de la tomograf&#237;a computarizada card&#237;aca, en b&#250;squeda de la calcificaci&#243;n arterial coronaria. De este grupo, 46 se excluyeron del an&#225;lisis ante la no informaci&#243;n del score de calcio. Hicieron la comparaci&#243;n con varios factores de riesgo, por medio de an&#225;lisis multivariado concluyendo que edad, presi&#243;n arterial sist&#243;lica, glucemia de ayuno, cantidad de componentes del s&#237;ndrome metab&#243;lico y n&#250;mero de vasos implicados permanecieron moderadamente asociados con calcificaci&#243;n arterial coronaria. Note que, b&#225;sicamente, los mismos factores est&#225;n presentes en el presente estudio.</p>
      <p>
        <bold>Conclusi&#243;n</bold>
      </p>
      <p>Con base en este estudio, se puede concluir que la prevalencia de enfermedad obstructiva coronaria es elevada en pacientes con insuficiencia hep&#225;tica avanzada en preoperatorio de trasplante hep&#225;tico y que, en el an&#225;lisis multivariado, solamente la hipertensi&#243;n arterial fue factor de riesgo independiente con significancia estad&#237;stica para el desarrollo de EAC. Por ser la hipertensi&#243;n un factor de riesgo cambiable, este hallazgo orienta hacia una pr&#225;ctica de actitudes terap&#233;uticas en la tentativa de evitarse o retrasarse el desarrollo de la EAC en el grupo de pacientes hepat&#243;patas cr&#243;nicos avanzados. </p>
      <p>
        <bold>Potencial Conflicto de Intereses</bold>
      </p>
      <p>Declaro no haber conflicto de intereses pertinentes.</p>
      <p>
        <bold>Fuentes de Financiaci&#243;n</bold>
      </p>
      <p>El presente estudio no tuve fuentes de financiaci&#243;n externas</p>
      <p>
        <bold>Vinculaci&#243;n Acad&#233;mica</bold>
      </p>
      <p>No hay vinculaci&#243;n de este estudio a programas de postgrado.</p>
      <p>
        <bold>Referencias</bold>
      </p>
    </body>
  </sub-article>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="en">Obstructive coronary disease in patients with chronic liver disease awaiting liver transplantation</article-title>
      </title-group>
      <abstract xml:lang="en">
        <p>BACKGROUND: Advanced liver failure (ALF) usually presents hypocholesterolemia. Nevertheless, some patients with ALF develops major coronary obstructive diseases with consequent increased risk or contraindication to liver transplantation. OBJECTIVE: To analyze the contribution of classical risk factors for coronary artery disease (CAD) in patients with ALF with and without obstructive coronary disease. METHODS: Evaluation of risk factors for CAD in 119 patients in a referral center for liver transplantation, with the following characteristics: patients older than 40 years of age with ALV who underwent coronary angiography. RESULTS: Obstructive coronary disease was detected in 21 (17.6%) of the cases. These patients had really low cholesterol levels, of which 129.0 &#177; 53.5 mg/dl averaging 117.0 mg/dl in liver disease patients with normal coronary arteries and 135.4 &#177; 51.7 mg/dl averaging 122.0 mg/dl in liver disease patients with obstructive coronary artery disease (P = 0.8215). In multivariate logistic regression, age, sex, body mass index and the presence of diabetes, smoking and alcohol consumption were not statistically significant in distinguishing groups. Nor was there an association with the etiology of the ALF. In turn, hypertension was proven to be relevant in association with CAD (P = 0.0474). CONCLUSION: Only hypertension was a risk factor with statistical significance for the development of CAD in patients with ALF awaiting liver transplantation. Because it is a modifiable risk factor, this finding guides the practice of therapeutic attitudes in an attempt to prevent or delay the development of CAD in these patients.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <kwd>Coronary artery disease</kwd>
        <kwd>liver transplantation</kwd>
        <kwd>risk factors</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p><undefined id="tx-body3"/>Obstructive coronary disease in patients with chronic liver disease awaiting liver transplantation</p>
      <p>
        <bold>Moacir Fernandes de Godoy<sup>I,II</sup>; Patricia de Oliveira Roveri<sup>I</sup>; Marcio Antonio dos Santos<sup>II</sup>; Flavio Correa Pivatelli<sup>II</sup>; Rita de C&#225;ssia Martins Alves da Silva<sup>II</sup>; Renato Ferreira da Silva<sup>II</sup></bold>
      </p>
      <p> Faculdade de Medicina de S&#227;o Jos&#233; do Rio Preto (FAMERP)<sup>1</sup>; Funda&#231;&#227;o Faculdade Regional de Medicina (FUNFARME)<sup>2</sup>, S&#227;o Jos&#233; do Rio Preto, SP - Brazil</p>
      <p>Mailing address</p>
      <p>
        <bold>ABSTRACT</bold>
      </p>
      <p><bold>BACKGROUND:</bold> Advanced liver failure (ALF) usually presents hypocholesterolemia. Nevertheless, some patients with ALF develops major coronary obstructive diseases with consequent increased risk or contraindication to liver transplantation. </p>
      <p><bold>OBJECTIVE:</bold> To analyze the contribution of classical risk factors for coronary artery disease (CAD) in patients with ALF with and without obstructive coronary disease.</p>
      <p><bold>METHODS:</bold> Evaluation of risk factors for CAD in 119 patients in a referral center for liver transplantation, with the following characteristics: patients older than 40 years of age with ALV who underwent coronary angiography.</p>
      <p><bold>RESULTS:</bold> Obstructive coronary disease was detected in 21 (17.6%) of the cases. These patients had really low cholesterol levels, of which 129.0 &#177; 53.5 mg/dl averaging 117.0 mg/dl in liver disease patients with normal coronary arteries and 135.4 &#177; 51.7 mg/dl averaging 122.0 mg/dl in liver disease patients with obstructive coronary artery disease (P = 0.8215). In multivariate logistic regression, age, sex, body mass index and the presence of diabetes, smoking and alcohol consumption were not statistically significant in distinguishing groups. Nor was there an association with the etiology of the ALF. In turn, hypertension was proven to be relevant in association with CAD (P = 0.0474).</p>
      <p><bold>CONCLUSION:</bold> Only hypertension was a risk factor with statistical significance for the development of CAD in patients with ALF awaiting liver transplantation. Because it is a modifiable risk factor, this finding guides the practice of therapeutic attitudes in an attempt to prevent or delay the development of CAD in these patients. </p>
      <p><bold>Key words: </bold>Coronary artery disease; liver transplantation; risk factors.</p>
      <p>
        <bold>Introduction</bold>
      </p>
      <p>Coronary artery disease (CAD) is the most common cause of myocardial ischemia, which may culminate in myocardial infarction, and it is the leading cause of death in western civilization. CAD is characterized by the formation of fatty deposits (atheroma) on the arteries wall, gradually blocking their light, especially in medium-sized arteries, among which are the coronary arteries<sup>1</sup>.</p>
      <p>Risk factors for CAD include hypercholesterolemia, increased levels of low-density lipoproteins (LDL) in the plasma, smoking, hypertension, diabetes, obesity, sedentary lifestyle, increased serum triglycerides levels, genetic predisposition, age and male sex, among which hypercholesterolemia stands out<sup>1</sup>.</p>
      <p>High levels of LDL are also capable of increasing the adhesion capacity of circulating monocytes, which adhere to damaged endothelial cells, are attracted by chemotaxis into the subendothelial region, accumulate and become macrophages, which phagocytize LDL until they become foam cells. These macrophages are also responsible for the release of several growth factors that act on smooth muscle cells and fibroblasts, forming more connective tissue and leading to fibrous plaques.</p>
      <p>A third action of high levels of LDL occurs on platelets. After endothelial injury, due to the retraction of endothelial cells, platelets may come into contact with the foam cells, which culminates with the adhesion, aggregation, and finally the formation of a mural thrombus, which occludes the artery lumen. That whole cycle that leads to formation of atheromatous plaques can be repeated continuously, providing progressive occlusion of the vessel<sup>1</sup>. </p>
      <p>Liver failure, however, is a disease characterized by severe loss of liver function due to some type of disturbance such as viral hepatitis, cirrhosis and liver disease due to drug or alcohol<sup>2</sup>.</p>
      <p>The liver is the most active cholesterol metabolism place, and in cases of advanced liver failure, loss of function of this organ leads to reduced plasma cholesterol.</p>
      <p>Mortality from liver failure ranges from 40 to 80%, and liver transplantation is the only therapeutic option capable of providing the patient with this disease a significant improvement in survival<sup>3</sup>. Transplantation is the established treatment for advanced liver disease and liver failure. Therefore, in the United States 4000 liver transplants are performed annually<sup>4</sup>. </p>
      <p>Liver cirrhosis can be of alcoholic origin. It is known that a moderate intake of alcohol has beneficial effects on atherosclerosis, by raising levels of high-density lipoprotein (HDL) in the plasma, which would be a contradiction to the occurrence of coronary artery disease in patients with liver failure. The role of HDL is to do the reverse cholesterol transport, leading it from the tissue to the liver, where it is metabolized and excreted<sup>1</sup>. This explains why an appropriate level of HDL reduces the risk for atherosclerosis.</p>
      <p>Based on these data, it would not be expected to find atherosclerosis in patients with liver failure awaiting liver transplantation. However, we found an overall prevalence of 16.2% of severe coronary artery disease (obstruction greater than 70% obstruction of the coronary arteries) in patients older than 50 years in the preoperative evaluation for liver transplantation, diagnosed by catheterization<sup>5</sup>. Plotkin et al<sup>6</sup> found, based on cardiac catheterization and dobutamine stress echocardiography, 5% of significant coronary artery disease (with obstruction of 70% or more of the coronary arteries) in patients older than 40<sup>6</sup>.</p>
      <p>It is known that the surgical mortality of patients with chronic liver disease undergoing liver transplantation is higher in the presence of obstructive coronary disease, and that mortality from cardiovascular disease continues to express itself in the post-operative period of patients who underwent transplantation<sup>7</sup>.</p>
      <p>Although coronary artery disease in patients diagnosed in the preoperative evaluation for liver transplantation is often considered an absolute contraindication, it does need not necessarily to be seen as such, but we know that the risks of morbidity and mortality in liver transplants in patients with coronary artery disease increase significantly, and they are also high in cases where transplant is performed after drug or surgical treatment of coronary artery disease<sup>8</sup>. However, there is no definition as to which risk factor best predicts the presence of obstructive coronary artery disease in patients with advanced liver failure<sup>9</sup>.</p>
      <p>The purpose of this study was to analyze patients with advanced liver failure with and without a diagnosis of coronary artery disease associated, to seek risk factors that could justify the development of obstructions.</p>
      <p>
        <bold>Materials and methods</bold>
      </p>
      <p>We reviewed medical records of 119 patients older than 40 suffering from advanced liver failure (ALF), who awaited in line for a liver transplant and who had undergone cardiac catheterization as part of preoperative clinical assessment procedures. The protocol of clinical assessment pre-liver transplantation at our institution included cardiac catheterization in all patients older than 40, since the stress test is often not feasible in this group. Moreover, they are often using vasodilators and beta-blockers. </p>
      <p>This review was performed to seek the presence or absence of risk factors for coronary heart disease factors. The factors considered were: age, sex, hypertension, diabetes, body mass index (BMI), smoking, alcohol consumption, total serum cholesterol, HDL, LDL and triglycerides, as well as the cause of liver failure.</p>
      <p>To calculate the frequency with which coronary artery may occur, we considered only patients with coronary artery with 50% light occlusion or more of at least one main branch compromised.</p>
      <p>In the statistical analysis, the continuous quantitative variables with Gaussian distribution were studied with the aid of Student's t test, while the nominal (or ordinal) qualitative or quantitative variables without Gaussian distribution were studied with the aid of Fisher's exact test or Mann-Whitney's test. The evaluation was complemented with a multiple logistic regression test.</p>
      <p>Cohort levels were: total cholesterol above 200 mg/dl, HDL below 40 mg/dl, LDL above 130 mg/dl and triglycerides above 150 mg/dl. Hypertensive patients were considered those with systolic blood pressure of 140 mmHg or greater; or diastolic blood pressure of 90 mmHg or greater; or those using antihypertensive medication. Diabetic patients were defined as those with glucose levels above 126 mg/dl or using oral hypoglycemic agents or insulin. Current smokers were those who smoked any amount of cigarettes or those who had quitted less than one year prior to coronary angiography. Alcohol drinkers were those who consumed more than two servings of alcohol a day. For use in logistic regression, age was considered by 55 (0) and more than 55 years (1); BMI was considered up to 29.9 kg/m<sup>2</sup> (0) and 30 or more kg/m<sup>2</sup> (1). The lipid values were not included in the logistic regression, because as a rule, they were often well below the maximum limits of normality.</p>
      <p>To analyze the causes of advanced liver failure, patients were divided into four groups: carriers of viruses (including hepatitis B virus, hepatitis C virus, or both), and alcoholics, patients with a combination of virus and alcohol, and patients with idiopathic or cryptogenic liver failure. An alpha error of 5% was assumed. P <underline>&lt;</underline> 0.05 was considered significant. The study was approved by the Ethics Committee of the Institution.</p>
      <p>
        <bold>Results</bold>
      </p>
      <p>The occurrence of coronary disease in 119 patients aged 40 and patients with advanced liver failure was 17.6% (21 of the cases). </p>
      <p>Sex and serum levels of cholesterol and its fractions were not a significant risk factor for the emergence of obstructive coronary disease. It was shown that patients with advanced liver failure had really low levels of cholesterol. On the one hand, the group of normal patients, the mean and standard deviation for total cholesterol was 129.0 &#177; 53.5 mg/dl with a median of 117.0 mg/dl. On the other hand, in the group of coronary patients, these values were respectively 135.4 &#177; 51.7 mg/dl with a median of 122.0 mg/dl (P = 0.8215; Mann-Whitney's test). The other results are shown in <xref ref-type="table" rid="en_154tab01-body3">Table 1</xref>. In the multivariate logistic regression, we included age, sex, BMI and the presence of hypertension, diabetes, smoking and alcohol consumption. Through this first analysis, we obtained P values below 0.20 only for age, sex, hypertension and diabetes. A new formulation with only these four variables showed that age, gender and diabetes were less relevant to the occurrence of CAD in severe liver disease patients. In turn, with P values of 0.0474, hypertension seemed to be relevant for the presence of CAD. </p>
      <p content-type="asset">
        <table-wrap id="en_154tab01-body3">
          <graphic xlink:href="1678-4170-abc-96-01-0026-00160-gt01-en.jpg"/></table-wrap>
      </p>
      <p>The final equation was presented as follows: logit Y = -3.727304 + 0.966403 [age] + 1.102597 [sex] + 1.032956 [hypertension] + 0.990118 [diabetes].</p>
      <p>Finally, there was some relationship between the established causes of advanced liver failure and development of coronary artery disease. This means that none of the etiologies of advanced liver failure in particular predisposes to the development of coronary artery disease.</p>
      <p>
        <bold>Discussion </bold>
      </p>
      <p>The occurrence of coronary disease found in this study (17.6%) was equivalent to the rate of 16.2% found by Carey WD et al, who considered only patients older than 50 with severe obstruction of coronary arteries<sup>5</sup>. The prevalence of 5%, a finding from the studies by Plotkin et al<sup>6</sup> on patients older than 40 with significant coronary obstruction was much lower than that obtained in this study. This prevalence of 17.6% is alarming because the risks of morbidity and mortality in patients with coronary artery disease, once undergoing liver transplantation, are significantly increased, even when coronary artery disease is treated with drugs or surgery before liver transplantation<sup>8</sup>. </p>
      <p>Age is a known immutable risk factor for the development of CAD<sup>1</sup>, so that its prevalence increases with age. In the patients studied, age did not appear as a risk factor for CAD development. </p>
      <p>Likewise, being male is also an immutable risk factor for CAD. However, in this study, there was no significant difference in the prevalence of coronary disease in males or females with advanced liver failure. This fact may be attributable to higher estrogen levels found in cirrhotic patients<sup>4</sup>.</p>
      <p>BMI is a measure of obesity that is a risk factor for CAD, and it is also associated with increased mortality after a possible liver transplant<sup>10</sup>. However, among the patients in this study, there was no significant difference between obesity in patients with or without coronary artery disease. Likewise, smoking, a known risk factor for CAD, was not very different in groups of patients with advanced liver failure with CAD and without CAD.</p>
      <p>Diabetes, in turn, also did not appear as a risk factor for CAD in patients with advanced liver failure. This is an unexpected result, once diabetes tends to be associated with other comorbidities such as obesity, hypertension and CAD itself. Knowing that diabetes usually develops in micro and macrovascular changes and with increased risk of atherosclerosis<sup>11</sup>, it would be expected that diabetes be confirmed as a risk factor for CAD, even in patients with advanced liver failure.</p>
      <p>With regard to alcoholism, it is known that a moderate intake of alcohol reduces the risk of atherosclerosis by increasing HDL levels. However, in excessive amounts, alcohol leads to hypertension and an increased risk of arterial occlusion<sup>12</sup>. Despite this, alcohol consumption was not confirmed as a risk factor for CAD in the patients analyzed.</p>
      <p>Hypertension is a powerful cardiovascular risk factor, which may prompt the development of atherosclerosis<sup>13</sup>. Furthermore, it is exacerbated by alcohol abuse<sup>12</sup> and it is often associated with diabetes<sup>11</sup>. As a general rule, lower blood pressure levels are found in cirrhotic patients<sup>13,14</sup>.</p>
      <p>With respect to serum levels of total cholesterol, HDL, LDL and triglycerides, no significant difference was found between the groups of liver disease patients with or without coronary artery disease. Due to chronic liver disease, these patients have reduced serum cholesterol levels, resulting from loss of liver function, but hypocholesterolemia would be a protective factor in relation to CAD. </p>
      <p>Finally, the different etiologies of liver disease, also showed no relation with the predisposition to CAD. It would be expected that at least the alcoholic etiology stand out somehow, either by its beneficial effects by increasing HDL and reducing cardiovascular risk, either because its harmful effects, raising blood pressure and increasing the risk of arterial occlusion<sup>12</sup>. However, alcohol consumption was not significantly different between the groups with or without coronary artery disease.</p>
      <p>Coronary angiography was used as the gold standard for diagnosis of obstructive coronary disease. In 2006, Tiukinhoy-Laing et al<sup>15</sup>, also used coronary angiography as the gold standard in 161 patients aged 45 or older in the preoperative evaluation for liver transplantation. They found a high prevalence of risk factors for atherosclerosis, in which half of the patients had hypertension or diabetes and two or more risk factors besides age were found in a number greater than half. The prevalence of 26% of moderate or severe atherosclerotic disease was found. In this group, most were men, elderly, and often suffering from hypertension or diabetes, a similar result as that found in this study.</p>
      <p>Other authors have sought alternative and non-invasive techniques such as, for example, Cardiac Computed Tomography. In 2008, McAvoy et al<sup>16</sup> evaluated 147 consecutive patients in pre-operative examinations for orthotopic liver transplantation with the aid of cardiac computed tomography, seeking coronary artery calcification. Out of that group, 46 were excluded from analysis for not informing the calcium score. They made a comparison with multiple risk factors through multivariate analysis concluding that age, systolic blood pressure, fasting glucose, amount of components of metabolic syndrome and number of vessels involved remained moderately associated with coronary artery calcification. Note that, basically, the same factors were found in this study.</p>
      <p>
        <bold>Conclusion</bold>
      </p>
      <p>Based on this study, we can conclude that the prevalence of obstructive coronary disease is high in patients with advanced liver failure in pre-operative examinations for liver transplantation and in the multivariate analysis, only hypertension was an independent risk factor with statistical significance for the development of CAD. Because hypertension is a modifiable risk factor, this finding guides the practice of therapeutic attitudes in an attempt to prevent or delay the development of CAD in patients with advanced chronic liver disease. </p>
      <p>
        <bold>Potential Conflict of Interest</bold>
      </p>
      <p>No potential conflict of interest relevant to this article was reported.</p>
      <p>
        <bold>Sources of Funding</bold>
      </p>
      <p>There were no external funding sources for this study.</p>
      <p>
        <bold>Study Association</bold>
      </p>
      <p>This study is not associated with any post-graduation program.</p>
      <p>
        <bold>References</bold>
      </p>
    </body>
  </sub-article>
</article>
